{"disease":{"id":"mucinous-cyst","name":"mucinous cyst"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07117045","title":"Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06638866","title":"AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04291651","title":"UCSF PANC Cyst Registry","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06706700","title":"Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas","phase":"","overall_status":"RECRUITING","enrollment_count":586,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT02005965","title":"Low Rectal Cancer Study (MERCURY II)","phase":"","overall_status":"UNKNOWN","enrollment_count":542,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT07262957","title":"Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT01995942","title":"Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial","phase":"","overall_status":"UNKNOWN","enrollment_count":246,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT01037049","title":"Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":237,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT02101775","title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":124,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03578445","title":"Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions","phase":"NA","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT03823833","title":"Oocyte Freezing for Fertility Preservation in Benign Ovarian Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT02978625","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03884179","title":"Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy","phase":"","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT02142803","title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01081262","title":"Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01459380","title":"Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01074411","title":"Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03188991","title":"Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"NanOlogy, LLC","has_results":true},{"nct_id":"NCT02283658","title":"Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02111941","title":"Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01489371","title":"EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}